Buy Tagrisso 80mg for NSCLC
What is NSCLC? Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 80-85% of all lung cancer diagnoses; the majority of patients will be diagnosed with non-operable, advanced-stage disease. It is caused due to mutation of Epidermal Growth Factor Receptor EFGR T790M. NSCLC is a heterogeneous aggregate of histologies, including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, it represents approximately 80% to 85% of all lung cancers. Palliative chemotherapy and/or radiotherapy represent the standard of care for this disease. Platinum-based doublets with third-generation agents are considered the standard of first-line advanced NSCLC treatment. How can Tagrisso 80mg help? Tagrisso 80 mg Tablet is a small molecule inhibitor of tyrosine kinase that is used for treating advanced non-small cell lung cancer (NSCLC) caused due to mutation of Epidermal Growth Factor Receptor EFGR T790M. It is the preferred choice to treat advanced lung cancer that has started sp...